Mannin Research Inc. is a biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics for vascular diseases. Utilizing a proprietary research platform, they are developing a unique molecule in the form of an eye drop for the treatment of Primary Open Angle Glaucoma, aiming to repair fluid flow in the eye and reduce intra-ocular pressure. Their innovative approach differentiates them in the market, and they have a deep pipeline of therapeutics targeting various vascular diseases, including Cystic Kidney Disease and Pediatric Glaucoma, indicating strong potential for growth and impact in the healthcare sector.
Something looks off?